EN DE
Check 40,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Gedeon Richter PLC (0QFP) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Gedeon Richter PLC stock £74.50, price £50.40, upside +47.8%, quality 81 out of 100. Rating: undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · Home Hungary · ISIN HU0000123096

GR Gedeon Richter PLC logo Broad data Oct 19, 2026

Gedeon Richter PLC

0QFP · LSE

Cheap (32% below fair value) and strong company.

Fair value £74.50 · Undervalued 
Quality 81/100 
Highly profitable · 23.3% net margin (TTM) 
Low debt 
Broad data 
Even on cautious assumptions the value is 11% above the price (£55.87). 
Mixed Growth (revenue 3y +8.4 %/yr in GBP) 
Wide moat 81/100 · thin data

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£119.31 £50.18 Fair Value £74.50 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 19, 2026.

How to read this chart

60‑month range £50.18 – £119.31 · fair‑value band £55.87 – £93.12 · the £50.40 price screens below the £74.50 fair value. As of Oct 19, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products.

Show moreShow less

It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives.

It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases.

In addition, it produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic.

Further, it engages in the provision of financial accounting, social and welfare, portfolio management, catering, carriage transportation, engineering, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment.

It has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management.

Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.

Stock analysis

Gedeon Richter PLC (0QFP) currently trades at £50.40, while our model-based Fair Value estimate is £74.50, implying the stock looks roughly 32% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of £122.85 per share, and 18 of the 25 models we run sit above the £50.40 price.

Bear case: the Asset-Based group reads lowest at £14.71, and 7 of the 25 models stay below the price. Data coverage for this calculation is high.

Scenario range: £55.87 (bear) to £93.12 (bull), the price of £50.40 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 81/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Gedeon Richter PLC reported revenue of £567B in FY2020 versus £390B in FY2016, a compound +9.8%/yr. Reported net income was £105B in FY2020, compounding +12.1%/yr from FY2016.

Key figures

Market cap £1.5T · P/S ratio 1.61 · Net margin 23.3% · Return on equity 16.2% · Return on assets (EBIT) 6.3% (5-year average) · Operating margin 33.0% · Revenue (TTM) £925B · EPS growth (quarter YoY) −26.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).

What moves the price

The share trades about 58% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at 48%, 0QFP screens cheaper than that median.

Fair Value models

Bear £55.87 Fair Value £74.50 Bull £93.12
Price £50.40 · Upside +47.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV £40.28 £46.84 £52.74 74
FCF DCF £91.47 £163.94 £297.64 73
Residual Income £26.72 £33.64 £49.69 72
All 25 models by family
DCF Models
FCF DCF £91.47 £163.94 £297.64 73
5Y Revenue Exit £54.76 £83.45 £120.72 69
5Y EBITDA Exit £67.66 £109.50 £160.49 71
5Y P/E Exit £68.58 £111.37 £158.95 67
10Y Revenue Exit £64.59 £96.00 £140.82 63
10Y EBITDA Exit £74.66 £115.64 £174.80 64
10Y P/E Exit £75.29 £117.04 £173.48 60
Earnings-Based
Graham-Dodd £24.12 £103.64 £141.63 61
Lynch FV £33.84 £48.35 £62.85 58
PEG = 1.0 £33.84 £48.35 £62.85 55
EPV £40.28 £46.84 £52.74 74
Dividend Discount
Gordon GGM £17.10 £38.93 £69.30 62
DDM Multi-Stage £17.10 £31.08 £40.31 63
Multiples
P/E Multiple £58.53 £78.04 £97.55 63
P/S Multiple £45.23 £60.31 £75.38 58
P/B Multiple £72.54 £96.72 £120.90 55
EV/EBIT £53.15 £69.27 £85.38 66
EV/EBITDA £61.91 £80.94 £99.97 67
EV/Revenue £39.32 £54.10 £68.89 54
Asset-Based
NCAV (Graham) £9.71 £14.71 £18.39 54
Growth DCF
Growth DCF £91.86 £162.06 £293.67 71
Rev-Margin DCF £54.76 £83.63 £120.22 69
Economic Profit
Residual Income £26.72 £33.64 £49.69 72
ROIC Compounder £44.93 £61.02 £83.72 68
Growth Earnings
Growth-Adj P/E £45.64 £65.20 £84.75 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 81/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 60
How much profit the company makes from its sales and capital
Quality Growth 69
Are margins and returns getting better?
Cashflow 95
Do the profits arrive as real cash?
Financial strength 90
Debt, balance sheet and risk of trouble
Investment 76
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 17
Distance to the 52-week high, does not count

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.0% (2016) → 19.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
not computed

Watch 0QFP, get fair value alerts →

Compare Gedeon Richter PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.11 $113.53 +44% vs 0QFP
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.00 ¥51.70 +10% vs 0QFP
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,884.90 ₹1,982.92 +5% vs 0QFP
Haleon plc HLN $9.07 $8.47 −7% vs 0QFP
Merck KGaA MRK €146.45 €108.83 −26% vs 0QFP
Galderma Group GALD CHF 182.85 CHF 112.84 −38% vs 0QFP
Teva Pharmaceutical Industries Limited TEVA $39.23 $20.74 −47% vs 0QFP
Takeda Pharmaceutical Company TAK $21.77 $11.26 −48% vs 0QFP
Sandoz Group SDZ CHF 80.50 CHF 40.87 −49% vs 0QFP
Divi's Laboratories Limited DIVISLAB ₹11,180.50 ₹1,566.89 −86% vs 0QFP

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Frequently asked questions

Is Gedeon Richter PLC (0QFP) overvalued or undervalued?
As of Oct 19, 2026, our model estimates a fair value of £74.50 versus a price of £50.40, about +48% upside (undervalued).
What is the fair value of 0QFP?
Our model-based fair value for Gedeon Richter PLC is £74.50 (as of Oct 19, 2026), built from audited fundamentals. The current price: £50.40.
What is the quality score of 0QFP?
Gedeon Richter PLC has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gedeon Richter PLC (0QFP)?
We do not set a price target; the yardstick is the fair value of £74.50 (as of Oct 19, 2026) from 25 valuation models. Cautious scenario £55.87, optimistic scenario £93.12. It is a calculation from audited fundamentals, not an analyst target.
What is the Gedeon Richter PLC stock forecast for 2026?
Our models put fair value at £74.50, about +48% upside versus a price of £50.40 (undervalued). Cautious scenario £55.87, optimistic scenario £93.12. The calculation is refreshed regularly with new filings.
What is the revenue of Gedeon Richter PLC (0QFP)?
Gedeon Richter PLC reported trailing-twelve-month revenue of about £925B (latest available figure, as of Oct 19, 2026).
What is the intrinsic value of Gedeon Richter PLC (0QFP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gedeon Richter PLC it is £74.50 per share (as of Oct 19, 2026), against a price of £50.40. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Gedeon Richter PLC stock overvalued or undervalued in 2026?
As of Oct 19, 2026, 0QFP trades below its calculated fair value: price £50.40, fair value £74.50, a gap of about +48% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QFP?
No. The price is what the market pays today (£50.40); the fair value is what the company's own numbers justify (£74.50). For Gedeon Richter PLC the two are £24.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gedeon Richter PLC worth?
The market values Gedeon Richter PLC at about £1.5T (market capitalisation, as of Oct 19, 2026). Per share that is £50.40; our models calculate a fair value of £74.50 per share.
What do the bullish and bearish scenarios say about 0QFP?
Our models span a range for Gedeon Richter PLC: cautious scenario £55.87, base £74.50, optimistic £93.12 per share (as of Oct 19, 2026, price £50.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0QFP from its 52-week high?
Gedeon Richter PLC trades at £50.40, about 58% below its 52-week high of £119.31 and at the low of £50.33 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of £74.50 is for.
Which stocks are comparable to Gedeon Richter PLC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gedeon Richter PLC stock attractive at the current price?
The data as of Oct 19, 2026: price £50.40, calculated fair value £74.50 (+48%), Quality Score 81/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QFP calculated?
We run Gedeon Richter PLC through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of £74.50 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Gedeon Richter PLC currently trades 32% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gedeon Richter PLC (0QFP)?
The closing price on Nov 20, 2026 was £50.40. Our model-based fair value is £74.50, about +48% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gedeon Richter PLC right now?
The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (£55.87). The market is more pessimistic than our downside scenario.

Key figures of Gedeon Richter PLC

How large is the market capitalisation of Gedeon Richter PLC (0QFP)?
The market capitalisation of Gedeon Richter PLC is £1.5T. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gedeon Richter PLC (0QFP)?
The price-to-sales ratio of Gedeon Richter PLC is 1.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Gedeon Richter PLC (0QFP)?
The net margin of Gedeon Richter PLC is 23.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gedeon Richter PLC (0QFP)?
The return on equity (ROE) of Gedeon Richter PLC is 16.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gedeon Richter PLC (0QFP)?
On an EBIT basis the return on assets of Gedeon Richter PLC is 6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gedeon Richter PLC (0QFP)?
The operating margin of Gedeon Richter PLC is 33.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Gedeon Richter PLC (0QFP)?
Earnings per share at Gedeon Richter PLC are down 26.2% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.